Skip to content

Study · Animal study (in vivo) · rat · 1994

13 results

Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.

Tomas FM, Chandler CS, Coyle P, Bourgeois CS, Burgoyne JL, Rofe AM

The Biochemical journal1 Aug 1994Cited by 11 (Europe PMC)

PMID8053901 (opens in a new tab)PMCIDPMC1137054 (opens in a new tab)DOI10.1042/bj3010769 (opens in a new tab)PepBankPUB-08053901
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, infusion of IGFs (IGF-I and LR3-IGF-I) alone significantly decreased food intake.

    In plain wordsIn rats with tumours, infusing IGF-I or the LR3 IGF-I analogue alone reduced how much they ate.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseFood intake
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    200 or 500 microgram/day · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of IGFs alone at either 200 or 500 microgram/day significantly decreased food intakes as well as circulating levels of insulin and glucose, and consequently failed to promote muscle protein accretion in the host.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, infusion of IGFs alone significantly decreased circulating insulin.

    In plain wordsIn rats with tumours, infusing IGF-I or the LR3 IGF-I analogue alone lowered blood insulin.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseCirculating insulin
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    200 or 500 microgram/day · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of IGFs alone at either 200 or 500 microgram/day significantly decreased food intakes as well as circulating levels of insulin and glucose, and consequently failed to promote muscle protein accretion in the host.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, infusion of IGFs alone significantly decreased circulating glucose.

    In plain wordsIn rats with tumours, infusing IGF-I or the LR3 IGF-I analogue alone lowered blood glucose.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseCirculating glucose
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    200 or 500 microgram/day · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of IGFs alone at either 200 or 500 microgram/day significantly decreased food intakes as well as circulating levels of insulin and glucose, and consequently failed to promote muscle protein accretion in the host.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, infusion of IGFs alone failed to promote muscle protein accretion in the host.

    In plain wordsIn rats with tumours, infusing IGF-I or the LR3 IGF-I analogue alone did not build muscle protein.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeMuscle protein accretion
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Protein and amino acid metabolism · Musculoskeletal
    Studied dose
    200 or 500 microgram/day · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of IGFs alone at either 200 or 500 microgram/day significantly decreased food intakes as well as circulating levels of insulin and glucose, and consequently failed to promote muscle protein accretion in the host.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, IGFs increased tumour growth, especially LR3-IGF-I.

    In plain wordsIn rats with tumours, IGF-I and especially the LR3 IGF-I analogue increased tumour growth.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseTumour growth
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Tumour growth was increased by the IGFs, especially by LR3-IGF-I
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, LR3-IGF-I, and to a lesser extent IGF-I, decreased rates of muscle protein synthesis, closely related to the final tumour burden.

    In plain wordsIn rats with tumours, the LR3 IGF-I analogue lowered muscle protein synthesis, a change closely related to tumour size.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseMuscle protein synthesis rate
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Protein and amino acid metabolism · Musculoskeletal
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of LR3-IGF-I, and to a lesser extent IGF-I, led to decreased rates of muscle protein synthesis and increased muscle protein breakdown, but each of these measures was closely related to the final tumour burden (r2 = 0.454 and 0.810 respectively; P < 0.01)
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, LR3-IGF-I, and to a lesser extent IGF-I, increased muscle protein breakdown, closely related to the final tumour burden.

    In plain wordsIn rats with tumours, the LR3 IGF-I analogue increased muscle protein breakdown, a change closely related to tumour size.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseMuscle protein breakdown
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Protein and amino acid metabolism · Musculoskeletal
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    Infusion of LR3-IGF-I, and to a lesser extent IGF-I, led to decreased rates of muscle protein synthesis and increased muscle protein breakdown, but each of these measures was closely related to the final tumour burden (r2 = 0.454 and 0.810 respectively; P < 0.01)
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, host weight changed by -1.1 g with LR3-IGF-I alone.

    In plain wordsIn rats with tumours, host weight barely changed with the LR3 IGF-I analogue alone.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableHost weight change with LR3-IGF-I alone
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Measurements

    host weight change
    −1.1 g
    LR3-IGF-I alone

    Source sentences

    Summary
    Insulin and LR3-IGF-I had a synergistic effect on host weight, which increased by 19.1 +/- 1.9, -1.1 +/- 4.7 and 37.9 +/- 1.5 g for insulin, LR3-IGF-I and combined treatments respectively.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, insulin and LR3-IGF-I together had a synergistic effect on host weight, with a gain of 37.9 g versus 19.1 g for insulin alone.

    In plain wordsIn rats with tumours, adding the LR3 IGF-I analogue to insulin gave more weight gain than insulin alone.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseHost weight with insulin plus LR3-IGF-I
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Comparator
    insulin alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Measurements

    host weight change
    37.9 g
    insulin plus LR3-IGF-I
    host weight change
    19.1 g
    insulin alone

    Source sentences

    Summary
    Insulin and LR3-IGF-I had a synergistic effect on host weight, which increased by 19.1 +/- 1.9, -1.1 +/- 4.7 and 37.9 +/- 1.5 g for insulin, LR3-IGF-I and combined treatments respectively.
    3 context sentences
    Summary · context
    The effect of insulin, either alone or in combination with LR3-IGF-I, was also investigated.
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, LR3-IGF-I alone had no positive effect on carcass protein accretion.

    In plain wordsIn rats with tumours, the LR3 IGF-I analogue alone did not build carcass protein.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeCarcass protein with LR3-IGF-I alone
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    but LR3-IGF-I had no positive effect on carcass protein accretion, either alone or in combination with insulin.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, LR3-IGF-I given with insulin had no positive effect on carcass protein accretion.

    In plain wordsIn rats with tumours, adding the LR3 IGF-I analogue to insulin did not add carcass protein.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeCarcass protein with LR3-IGF-I plus insulin
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Comparator
    insulin alone
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Source sentences

    Summary
    but LR3-IGF-I had no positive effect on carcass protein accretion, either alone or in combination with insulin.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In tumour-bearing rats, LR3-IGF-I decreased the amount of carcass fat by 30%.

    In plain wordsIn rats with tumours, the LR3 IGF-I analogue reduced carcass fat.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseCarcass fat
    Study

    ratn: not reported in source

    rats bearing a mammary adenocarcinoma
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · osmotic minipump · 6-7 daysAs given in this study (rat).

    Measurements

    carcass fat decrease
    30%
    LR3-IGF-I

    Source sentences

    Summary
    Similarly, the amount of carcass fat was increased almost 2-fold by insulin treatment, whereas it was decreased by 30% by LR3-IGF-I.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.
  13. 13LabIn vitro (cells)Efficacy outcome

    In cell culture, IGFs (IGF-I and LR3-IGF-I) did not promote growth of the mammary adenocarcinoma.

    In plain wordsIn cells, IGF-I and the LR3 IGF-I analogue did not make the tumour cells grow.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeAdenocarcinoma cell growth in culture
    Study

    n: not reported in source

    mammary adenocarcinoma cell culture
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    even though these peptides did not promote growth of the adenocarcinoma in cell culture.
    2 context sentences
    Summary · context
    The effects of insulin-like growth factor-1 (IGF-I), and a more potent variant LR3-IGF-I, which binds poorly to IGF-binding proteins, were investigated in rats bearing a mammary adenocarcinoma.
    Summary · context
    Peptides were infused via osmotic minipumps for 6-7 days after tumour size reached 5% of body weight.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.